Pfizer extends King Pharma tender offer; Canadian court orders Celgene to release data;

 @FiercePharma: Teva to lay off 200 at idled Irvine plant. Story | Follow @FiercePharma

> The U.K. pharma industry association has said the government's forthcoming Cancer Drugs Fund could increase the problems of regional differences in prescribing. News

> Countries that vaccinate babies against rotavirus, which can cause severe diarrhea and kill in days, have significantly reduced the number of children admitted to hospitals with the disease, a report showed. Item

> Pfizer extended its tender offer to acquire King Pharmaceuticals for the third time while the companies await U.S. regulatory approval for the $3.6 billion deal. Report

> If HHS Secretary Kathleen Sebelius truly wants to make the FDA a "world-class" regulatory agency, she must take seriously the charges of misconduct and mismanagement within the FDA's Center for Devices and Radiological Health, the Project on Government Oversight contends. News

> U.S. biotechnology firm Celgene must provide information to Canadian regulators who want to review the price it charges for its Thalomid drug, Canada's Supreme Court ruled. Report

> A year after UNITAID approved an international patent pool to bolster access to needed HIV and AIDS meds, the U.S. government has gotten behind the initiative and is urging the WHO to embrace the concept. Story

> U.S. health officials unveiled steps to streamline reviews of medical devices and deferred decisions on contentious issues the industry feared would slow approval of new products. Story

Biotech News

 @FierceBiotech: MannKind slammed with FDA demand for new Afrezza trials. Item | Follow @FierceBiotech

 @JohnCFierce: Rodman's Simeonidis sees an 18 month delay on Afrezza, calls on the FDA to make the CRLs public. Amen on that. Follow @JohnCFierce

> FDA panel rejects Lilly's Amyvid app, but sees how it can work. Report

> Biotech VC investing grows 3 percent in 2010. Article 

>  CHMP backs Novartis' Gilenya as EMA shoots down cladribine. News

And Finally... This is your brain on music, courtesy of Nature Neuroscience. Article

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.